Finerenone shows promise in slowing chronic kidney disease progression in non-diabetic patients, according to recent global ...

The U.S. Food and Drug Administration has approved Vera Therapeutics' drug to treat patients with a ​potentially ...

TRUTAKNA is the first and only available therapy that binds both B-cell activating factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), addressing the immunological drivers at the source of IgA ...

When Vera Therapeutics in-licensed atacicept from Merck KGaA about six years ago, patients with IgA nephropathy (IgAN) had no ...

A surprising finding has revealed that the kidneys may control water retention through an additional pathway beyond the one ...

Noticing your socks leave deep marks around your ankles at the end of the day can easily be shrugged off. It is incredibly ...

A 26-year-old’s vitamin D habit led to kidney failure and dialysis. Here is why you should never skip the blood test before ...

Vera Therapeutics’ atacicept, to be marketed as Trutakna, will go up against Novartis, Otsuka and possibly Vertex in the kidney disease primary IgA nephropathy after receiving an accelerated FDA ...

The phase 2 BESTOW trial is testing calcineurin inhibitor-free maintenance therapy with tegoprubart vs tacrolimus in kidney transplant recipients.

Learn what conditions an endocrinologist treats, including diabetes, thyroid and hormone disorders, and discover practical ...

BridgeBio’s Attruby preserves kidney function in patients with transthyretin amyloidosis cardiomyopathy, an effect that is “distinct” from other drugs in this space, according to Jefferies.